Thromboembolic risk in patients with lung cancer receiving systemic therapy.

ABSTRACT: In this retrospective study, we investigated the influence of chemotherapy and immunotherapy on thromboembolic risk among United States Veterans with lung cancer during their first 6 months (180 days) following initiation of systemic therapy. Included patients received treatment with common front-line agents that were divided into four groups: chemotherapy alone, immunotherapy alone, combination of chemo- and immunotherapies, and molecularly targeted therapies (control group). The cohort experienced a 7·4% overall incidence of thrombosis, but the analysis demonstrated significantly different rates among the different groups. We explored models incorporating multiple confounding variables as well as the competing risk of death, and these results indicated that both chemo- and immunotherapie

SUBMITTER: Madison CJ 

PROVIDER: S-EPMC8283785 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature